Health Economics, Financing and Strategic Purchasing

Introduction and context

Health systems must convert scarce resources into health, protection from financial hardship, responsiveness, and equity. Economics is therefore not concerned merely with reducing expenditure. It asks how resources should be mobilised, pooled and allocated when needs are extensive, budgets limited, information imperfect and health outcomes difficult to value. Financing arrangements shape who pays, when they pay, what services are covered, and whether illness causes poverty. Purchasing arrangements shape how pooled funds are translated into services and how providers are held accountable.

For health-care managers, the central task is strategic: to align revenue collection, pooling, benefit design, provider payment and performance measurement with national health objectives. A technically efficient payment method can still be inequitable; a generous benefit package can be fiscally unsustainable; and a cost-effective intervention may remain inaccessible if the delivery system lacks trained staff or medicines.

Learning objectives

By the end of this chapter, the reader should be able to:

1. Compare taxation, social insurance, private insurance and out-of-pocket financing.
2. Explain revenue collection, pooling, risk sharing and strategic purchasing.
3. Analyse risk adjustment and provider-payment methods.
4. Apply incremental cost-effectiveness analysis and interpret health technology assessment.
5. Evaluate financial protection, equity and sustainability.
6. Recommend governance and purchasing reforms in a national or organisational setting.

1. The economic problem in health care

Health care exhibits several features that distinguish it from ordinary consumer markets:

• Uncertainty: illness, treatment response and future expenditure are uncertain.
• Asymmetric information: clinicians generally know more than patients about diagnosis and treatment.
• Externalities: vaccination and infection control benefit people beyond the immediate recipient.
• Merit-good considerations: societies may choose to provide care even when individuals cannot pay.
• Provider influence over demand: professional advice can affect the volume and type of care consumed.
• Equity concerns: equal treatment for equal need, and greater support for disadvantaged groups, may be social objectives.

The opportunity cost of a health decision is the health forgone when the same resources cannot be used elsewhere. A new oncology medicine may improve survival, but its budgetary cost could displace primary-care, vaccination or maternal-health services. Economic evaluation makes this trade-off visible; it does not by itself determine the ethical answer.

Two distinctions are essential. Efficiency concerns achieving the greatest valued health and welfare from available resources. Equity concerns the fairness of distribution across people, groups and generations. A policy can be efficient but inequitable, or equitable but inefficient. Health policy must make both dimensions explicit.

2. Health financing architecture

A financing system has three core functions:

1. Revenue raising: obtaining funds through taxes, contributions, premiums, grants or payments.
2. Pooling: accumulating prepaid funds so that the costs of some members are shared across the population.
3. Purchasing: using pooled resources to obtain services from providers.

These functions should be distinguished from service provision. A ministry may collect taxes and purchase services from public and private providers; an insurer may pool and purchase but not deliver care; a hospital may provide care without bearing population-level insurance risk.

Figure: The principal functions of health financing and their relationship to outcomes.

2.1 Taxation

Tax-financed systems use general revenues, including income, consumption, corporate, property and excise taxes. Their strengths include broad risk sharing, the ability to subsidise people without formal employment, and relatively low point-of-service collection costs. Progressive income taxation can support vertical equity, although consumption taxes may be regressive unless offset by exemptions or transfers.

Tax financing remains vulnerable to fiscal cycles, competing government priorities, weak tax administration and political pressure to limit public spending. Earmarked taxes can create a visible link to health but may reduce budget flexibility and produce unstable revenue if consumption patterns change.

2.2 Social health insurance

Social insurance usually relies on compulsory payroll contributions, often supplemented by government transfers for dependants, informal workers and low-income households. It can create an explicit entitlement and a degree of institutional autonomy. However, payroll financing can exclude informal workers, increase labour costs, fragment risk pools and encourage contribution evasion. Multiple funds require strong regulation and mechanisms for cross-subsidy.

2.3 Private insurance

Private insurance may be voluntary or employer-sponsored. It can provide additional choice, faster access or coverage beyond a public package. Yet voluntary markets face adverse selection: people expecting high costs are more likely to enrol. Insurers may respond through premiums, exclusions, deductibles or underwriting. Regulation is required to prevent risk selection, misleading products and discrimination, while preserving solvency and consumer protection.

2.4 Out-of-pocket payments

Out-of-pocket (OOP) payment occurs when a patient pays directly at the time of service, including fees, deductibles, co-insurance and medicine purchases. It is administratively simple but weak at pooling risk. It can deter necessary care, encourage late presentation and expose households to catastrophic expenditure. User charges may sometimes reduce low-value demand, but they are a blunt instrument because patients often cannot judge clinical value and poor households are most sensitive to price.

A useful household indicator is the catastrophic health expenditure rate:

Here, N is the number of households, OOPᵢ is household i’s out-of-pocket health spending, Cᵢ is its chosen measure of capacity to pay, z is a policy threshold, and I(·) equals 1 when the condition is true and 0 otherwise. The measure is a proportion, not a currency amount. Different studies define capacity and thresholds differently, so comparisons require methodological caution.

2.5 Comparing financing mechanisms

3. Pooling and risk adjustment

Pooling separates payment from the unpredictable need for care. A large, diverse pool generally improves predictability because high costs are spread across many members. Pooling is weakened by small fragmented schemes, annual movement between pools, exclusions for chronic disease and large uncovered populations.

Risk adjustment transfers resources among purchasers or insurers according to expected need rather than observed expenditure. Its purpose is to prevent organisations serving older, poorer or sicker populations from being penalised and to reduce incentives for risk selection. A simplified expected-cost model is:

E(Cᵢ) is predicted annual cost for person i; α is the intercept; β₁–β₄ are estimated coefficients; and the explanatory variables represent measured risk characteristics. The model is used for allocation, not for denying care. It assumes that included variables predict legitimate differences in expected need and that data are sufficiently accurate.

Risk adjustment can use demographic variables, diagnoses, prior utilisation, disability, socioeconomic status or regional factors. Diagnosis-based models improve prediction but may encourage coding intensity. Prior expenditure may reproduce inequitable access patterns. Socioeconomic variables can improve fairness but raise privacy and classification concerns. Risk adjustment should therefore be combined with audits, transparency, appeals and monitoring for gaming.

4. Strategic purchasing

Passive purchasing pays providers according to historical budgets or open-ended claims. Strategic purchasing continuously asks:

• Which services should be purchased for which population?
• From which providers and at what price?
• Under what quality, access and reporting conditions?
• How should payment change when outcomes, equity or efficiency improve?

Strategic purchasing requires a purchaser capable of population analysis, benefit design, contracting, data interpretation and provider oversight. It also requires a clear separation of roles: government sets policy and regulation; purchasers allocate funds and contract; providers deliver care; citizens exercise rights and provide feedback.

4.1 Benefit design

A benefit package should specify covered services, eligibility, referral rules, medicines, diagnostics, exclusions, waiting conditions and maximum limits. Comprehensive lists are not automatically affordable. Explicit prioritisation is preferable to implicit rationing through stock-outs, waiting times or informal payments. Decisions should consider disease burden, effectiveness, cost, equity, feasibility and financial protection.

4.2 Provider-payment methods

No method is universally superior. Blended payment is often preferable: for example, a base capitation payment for primary care, quality incentives for continuity and prevention, and separate adjustment for unusually costly cases. Contracts should define quality standards, data obligations, sanctions, dispute procedures and patient protections.

The incentives of payment methods can be analysed using principal–agent theory. The purchaser (principal) cannot observe every clinical decision made by the provider (agent). Payment design, audit and professional norms must therefore balance autonomy with accountability. Excessive measurement can displace intrinsic motivation, while weak monitoring permits overbilling or under-service.

5. Economic evaluation and cost-effectiveness

Economic evaluation compares alternative courses of action in terms of both costs and consequences. The principal forms are:

• Cost-minimisation analysis: appropriate only when outcomes are demonstrably equivalent.
• Cost-effectiveness analysis (CEA): outcomes are measured in natural units, such as cases detected or life-years gained.
• Cost-utility analysis (CUA): outcomes incorporate quality and quantity of life, commonly using QALYs or DALYs.
• Cost-benefit analysis: both costs and benefits are expressed in monetary terms.
• Budget impact analysis: estimates the short- to medium-term affordability for a specified payer and population.

The incremental cost-effectiveness ratio is:

C₁ and C₀ are costs of the new and comparator interventions; E₁ and E₀ are their effects. The numerator is currency and the denominator is effect units, so the ICER has units such as currency per QALY gained. The comparison is meaningful only when the new intervention produces additional effect; dominated options should be removed first. An intervention is strictly dominated if another option costs less and produces more effect. Extended dominance occurs when a combination of alternatives provides effects more efficiently than the option under review.

Costs and outcomes occurring in different years should normally be discounted. A general present-value expression is:

Xₜ is a cost or outcome in year t, r is the annual discount rate expressed as a decimal, and t is the time period. The discount rate and perspective must follow the relevant national guidance. Discounting is not a substitute for sensitivity analysis.

Worked example

An immunisation programme costs $1,200,000 and prevents 10,000 disability-adjusted life years (DALYs) relative to no programme. An alternative programme costs $1,800,000 and prevents 12,000 DALYs. The incremental cost is $600,000 and the incremental effect is 2,000 DALYs prevented. Therefore:

The result is $300 per additional DALY prevented. Whether this represents good value depends on the decision rule, budget, opportunity cost and distributional effects. A threshold must not be treated as an automatic entitlement to fund an intervention.

6. Health technology assessment

Health technology assessment (HTA) is a multidisciplinary process examining the clinical, economic, ethical, organisational, legal and social consequences of a technology. “Technology” includes medicines, devices, diagnostics, procedures, digital tools and service models.

A robust HTA process usually includes:

1. defining the decision problem and perspective;
2. identifying the relevant comparator;
3. reviewing clinical effectiveness and safety;
4. estimating costs and outcomes;
5. assessing uncertainty through deterministic and probabilistic sensitivity analysis;
6. considering budget impact, feasibility and equity;
7. consulting stakeholders;
8. issuing a transparent recommendation and revisiting it when evidence changes.

Evidence from controlled trials may have high internal validity but limited generalisability. Real-world evidence can describe adherence, utilisation and safety at scale, but confounding and selection bias must be managed. Modelling is often necessary for long-term diseases; assumptions about survival, adherence, prices and utilities should be visible and tested.

QALYs combine length and quality of life. If a person lives two years at a utility of 0.8, the undiscounted outcome is 1.6 QALYs. Utilities are value weights and may not fully reflect social preferences, disability rights or the value of a life extension for people with severe illness. DALYs measure health loss through years of life lost and years lived with disability. Neither measure captures every ethical consideration.

7. Financial protection and equity

Financial protection means that using needed health services does not expose households to excessive direct payment or loss of basic living standards. Indicators include OOP share, catastrophic expenditure, impoverishing expenditure, unmet need, foregone care and medicine affordability.

Protection requires more than insurance enrolment. A nominally covered person may face transport costs, unavailable medicines, balance billing, co-payments or long waiting times. Effective coverage combines access, quality and financial protection. Policies include free or subsidised primary care, essential medicines, exemption schemes, maximum annual liabilities, transport support and automatic entitlement for vulnerable groups.

Equity analysis should examine financing incidence, service utilisation and outcomes by income, gender, geography, ethnicity, disability, age and migration status. Universalism can be progressive when higher-income groups contribute more while everyone receives a meaningful package. Targeting can concentrate resources but may create stigma, exclusion errors and administrative costs.

8. Governance, ethics and regulation

Financing decisions involve distributive ethics. Transparent criteria should address need, effectiveness, severity, solidarity, cost and feasibility. Procedural fairness requires publicity, reasons for decisions, opportunities for appeal, consistency and revision when evidence changes.

Key governance risks include corruption, procurement collusion, false claims, upcoding, informal payments, conflicts of interest and misuse of patient data. Controls include separation of duties, competitive procurement, audit trails, open contracting, whistle-blower protection, independent oversight and sanctions proportionate to harm.

Digital claims systems and artificial intelligence can identify anomalous billing, forecast demand and support risk adjustment. They can also reproduce historical inequities, incorrectly flag legitimate care or expose sensitive information. AI should be subject to data-quality assessment, human review, explainability appropriate to the decision, cybersecurity, bias testing and a clear accountability chain. Automation must support—not replace—clinical and administrative judgment.

9. Contemporary strategic issues

Several developments are reshaping financing. Ageing and multimorbidity increase demand for coordinated chronic-care purchasing. Climate-related events create volatile expenditure and require resilient facilities and emergency financing. Antimicrobial resistance challenges conventional short-term value calculations because preserving effectiveness has social value. High-cost gene and cell therapies raise questions about instalment payments, outcomes-based contracts and long-term uncertainty. Digital platforms create new opportunities for remote monitoring but may fragment care and generate vendor dependence.

Fiscal sustainability should be assessed dynamically. Managers should model demographic change, price growth, technology adoption, workforce supply, utilisation and revenue scenarios. Cost containment that reduces necessary care may shift costs to households or produce worse outcomes. Better purchasing generally seeks value: prevention, continuity, integrated care, generic procurement, reduction of low-value services and payment linked to outcomes that are valid and difficult to manipulate.

Applied case: purchasing reform in the Republic of Lydora

This is a fictional illustrative case.

Background

Lydora has a tax-funded national health service and three regional purchaser offices. Primary care is nominally free, but hospitals receive historical budgets and specialists are paid fee-for-service. Rural residents report medicine shortages and travel costs. The national budget is under pressure from diabetes, cardiovascular disease and avoidable admissions.

Problem

Regional purchasers spend different amounts on similar populations. Rural areas have older and poorer residents but receive less per person because allocations are based on historical expenditure. Hospitals increase diagnostic activity, while preventive follow-up is weak. Household surveys show rising medicine-related OOP spending.

Analysis

The ministry separates three problems. First, allocation is inequitable because it lacks risk adjustment. Second, payment encourages activity rather than coordination. Third, the benefit package covers consultations but does not reliably finance essential medicines. A rapid HTA identifies generic antihypertensive treatment and nurse-led follow-up as high-value interventions, while several low-value imaging practices are unsuitable for routine use.

Approach

Lydora introduces a national pool with a risk-adjusted formula using age, diagnosed chronic disease, poverty and rurality. It establishes an essential medicines fund and caps annual OOP exposure for low-income households. Primary-care practices receive risk-adjusted capitation, a small quality component for blood-pressure control and continuity, and separate payments for outreach in remote areas. Hospitals move gradually from historical budgets toward case-based payments, with safeguards for teaching, emergencies and unusually complex cases.

The purchaser publishes contracts, audits coding, monitors waiting times and reports outcomes by region and income group. An independent HTA committee reviews expensive technologies, while a citizen panel contributes to deliberation on benefit priorities.

Outcome

After two years, reported medicine-related OOP spending falls among protected households, follow-up improves and regional allocations more closely reflect need. However, hospital coding intensity rises and some providers report that quality indicators do not capture social complexity. The purchaser responds by auditing diagnoses, refining the risk model and adding patient-reported continuity measures rather than abandoning the reform.

Learning points

The case demonstrates that strategic purchasing is a system reform rather than a single payment change. Pooling, risk adjustment, benefit design, provider payment, data governance and public accountability must operate together. Early outcome improvements should be interpreted cautiously because attribution is difficult and implementation effects may take time.

Challenges and limitations

Economic analysis cannot eliminate uncertainty or ethical disagreement. Cost data may be incomplete, informal care may be excluded, and clinical evidence may not transfer across settings. ICERs can undervalue equity or severe illness unless distributional effects are separately assessed. Risk adjustment can be gamed, and performance payment can narrow attention to measured indicators. Pooling reforms may face opposition from organisations that benefit from fragmentation. Finally, fiscal sustainability is political as well as technical: priorities reflect social choices about solidarity and the role of the state.

Best-practice principles for managers

1. Define the population, objectives and decision perspective before selecting a financing instrument.
2. Prefer prepaid, compulsory and broad-based pooling for essential care.
3. Protect poor and high-need groups through explicit subsidies and risk adjustment.
4. Separate purchasing from provision where this improves accountability, while preserving coordination.
5. Use blended provider payment and monitor both underprovision and overprovision.
6. Combine CEA with budget impact, equity, feasibility and ethical analysis.
7. Make benefit decisions transparent, reviewable and evidence-informed.
8. Track financial protection with household and service-use data, not enrolment alone.
9. Audit coding, procurement and algorithms; protect privacy and due process.
10. Engage clinicians, patients, communities and finance authorities in implementation.

Chapter Summary

Health financing consists of revenue raising, pooling and purchasing. Taxation and social insurance can support broad solidarity, while private insurance may supplement public coverage but requires regulation. Out-of-pocket payment provides little risk protection and can create financial hardship. Pooling spreads uncertain costs, and risk adjustment allocates resources according to expected need while limiting risk selection.

Strategic purchasing links pooled funds to population needs, provider performance and explicit contracts. Payment methods create different incentives: fee-for-service can increase activity, capitation can encourage prevention but risk under-service, and case-based payment can promote efficiency while creating coding and discharge risks. Blended payment, audit and quality monitoring are usually necessary.

Economic evaluation compares costs and outcomes; the ICER expresses additional cost per additional unit of effect. HTA broadens this analysis to clinical, ethical, organisational and social consequences. Financial protection must be assessed through actual household burdens and access, not insurance membership alone. Sustainable reform requires transparent governance, equity analysis, data protection, public participation and continual evaluation.

Key Terms

Health economics: Study of how scarce resources are allocated to produce health and welfare.

Health financing: Revenue raising, pooling and purchasing of health services.

Revenue raising: Obtaining funds through taxes, contributions, premiums or other sources.

Pooling: Combining prepaid resources to share health-care risks across people.

Strategic purchasing: Deliberate allocation of pooled funds according to population needs, provider performance and policy objectives.

Out-of-pocket payment: Direct payment by a patient at the time of receiving care.

Financial protection: Protection against financial hardship caused by health-care use.

Risk adjustment: Redistribution of funds based on expected differences in health-care need or cost.

Adverse selection: Disproportionate enrolment of people with high expected health costs.

Provider payment: Method used to remunerate health-care providers.

Capitation: Fixed payment per enrolled person for a defined period and service set.

Case-based payment: Payment for a defined episode or diagnosis-related group.

Health technology assessment: Multidisciplinary assessment of a technology’s consequences and value.

Cost-effectiveness analysis: Comparison of incremental costs and effects in natural health units.

Cost-utility analysis: Economic evaluation using utility-based outcomes such as QALYs.

ICER: Incremental cost-effectiveness ratio, or additional cost divided by additional effect.

QALY: Quality-adjusted life-year combining length and quality of life.

DALY: Disability-adjusted life-year representing health loss from premature death and disability.

Budget impact analysis: Estimate of the financial consequences of adopting an intervention for a specified payer.

Risk selection: Attempts by purchasers or insurers to attract low-risk or avoid high-risk members.

Review Questions

Short Answer Questions

1. What are the three principal functions of health financing?
2. Why can out-of-pocket payment undermine financial protection?
3. Define risk adjustment and state its main purpose.
4. What is the difference between cost-effectiveness analysis and budget impact analysis?
5. Give one strength and one risk of capitation payment.

Long Answer Questions

1. Compare taxation, social health insurance and private insurance in relation to equity, pooling and sustainability.
2. Explain how strategic purchasing can improve provider accountability and health-system performance.
3. Discuss the ethical and methodological limitations of using ICERs in national coverage decisions.
4. Analyse the relationship between provider-payment incentives and quality of care.
5. Design a governance framework for an HTA agency operating in a middle-income country.

Analytical / Application Questions

1. A new service costs $900,000 and produces 3,000 additional QALYs compared with current care. Calculate the ICER and identify the additional information required before recommending adoption.
2. A region with older, poorer and more rural residents receives less funding because allocations are based on historical expenditure. Propose a risk-adjustment approach and identify two risks in implementing it.
3. A purchaser observes rising hospital activity, unchanged outcomes and increasing OOP medicine spending. Diagnose the likely financing and purchasing problems and recommend a phased reform plan.

Multiple Choice Questions with Answers

Question 1

Which financing function combines prepaid resources so that the costs of illness are shared across members?

A. Revenue raising

B. Pooling

C. Purchasing

D. Service provision

Correct Answer: B. Pooling

Question 2

What is the principal purpose of risk adjustment between health purchasers?

A. To reward providers for every additional service

B. To eliminate all uncertainty about future expenditure

C. To allocate funds according to expected need and reduce risk selection

D. To replace clinical quality measurement

Correct Answer: C. To allocate funds according to expected need and reduce risk selection

Question 3

A new intervention costs $600,000 more than its comparator and produces 2,000 additional DALYs prevented. What is its ICER?

A. $30 per DALY prevented

B. $300 per DALY prevented

C. $1,200 per DALY prevented

D. $3,000 per DALY prevented

Correct Answer: B. $300 per DALY prevented

Question 4

Which provider-payment method pays a fixed amount for each enrolled person over a specified period?

A. Fee-for-service

B. Salary

C. Capitation

D. Case-based payment

Correct Answer: C. Capitation

Question 5

Which situation represents strict dominance in economic evaluation?

A. An option costs more and produces more health

B. An option costs less and produces less health

C. An option costs more and produces less health than another option

D. Two options have equal costs and different perspectives

Correct Answer: C. An option costs more and produces less health than another option

Question 6

Which statement best describes health technology assessment?

A. It considers only the acquisition price of medicines

B. It is a multidisciplinary assessment of a technology’s consequences and value

C. It guarantees that every clinically effective technology will be funded

D. It replaces public deliberation with an ICER threshold

Correct Answer: B. It is a multidisciplinary assessment of a technology’s consequences and value

Question 7

Which payment method has the clearest direct incentive to increase the volume of billable services?

A. Fee-for-service

B. Global budget

C. Salary

D. Capitation

Correct Answer: A. Fee-for-service

Question 8

Why may a nominally insured household still experience inadequate financial protection?

A. Insurance always removes transport costs

B. Coverage may coexist with co-payments, unavailable medicines or balance billing

C. Pooling guarantees that all services are available locally

D. Risk adjustment eliminates all household expenditure

Correct Answer: B. Coverage may coexist with co-payments, unavailable medicines or balance billing

Question 9

In the present-value formula, what does the discount rate represent?

A. The number of people in the risk pool

B. The annual rate used to convert future values into present values

C. The probability that a claim is fraudulent

D. The difference between average and marginal cost

Correct Answer: B. The annual rate used to convert future values into present values

Question 10

Which is a recognised governance risk when artificial intelligence is used to detect anomalous claims?

A. It necessarily improves equity without monitoring

B. It makes privacy protection unnecessary

C. It may reproduce biased historical data and incorrectly flag legitimate care

D. It removes the need for human accountability

Correct Answer: C. It may reproduce biased historical data and incorrectly flag legitimate care